1. Вербицкая Е.В. Доказательная медицина: основные понятия, принципы поиска и оценки информации: Методическое пособие. Под ред. А.С. Колбина. СПб.: РИЦ ПСПбГМУ, 2017. 36 с.
2. Галанкин Т.Л., Вербицкая Е.В. Фармакоэпидемиология: Методическое пособие. Под ред. А.С. Колбина. СПб.: Издательство СПбГМУ, 2015. 40 с.
3. Оценка медицинских технологий, 2013 г. Под общ. ред. Ю.Б. Белоусова. М.: Издательство ОКИ, 2013. 40 с.
4. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19): Временные методические рекомендации. Версия 4 (27.03.2020). URL: https://static-3.rosminzdrav.ru/system/attachments/attaches/000/049/877/original/COVID19_recomend_v4.pdf
5. Управление клиническими исследованиями. Под общ. ред. Д.Ю. Белоусова, С.К. Зырянова, А.С. Колбина. 1-е изд. М.: Буки Веди: Издательство ОКИ, 2017. 676 с.
6. Шкурупий В.А., Курунов Ю.Н., Яковченко Н.Н. Лизосомотропизм — проблемы клеточной физиологии и медицины. Новосибирск: Издательство Новосибирского государственного медицинского университета, 1999. 289 с.
7. Alhazzani W., M øller M.H., Arabi Y.M., Loeb M., Gong M.N., Fan E., Oczkowski S., Levy M.M., Derde L., Dzierba A., Du B., Aboodi M., Wunsch H., Cecconi M., Koh Y., Chertow D.S., Maitland K., Alshamsi F., Belley-Cote E., Greco M., Laundy M., Morgan J.S., Kesecioglu J., McGeer A., Mermel L., Mammen M.J., Alexander P.E., Arrington A., Centofanti J.E., Citerio G., Baw B., Memish Z.A., Hammond N., Hayden F.G., Evans L., Rhodes A. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit. Care Med., 2020. doi: 10.1097/CCM.0000000000004363
8. Aronson J.K., Ferner R.E. Drugs and the renin-angiotensin system in COVID-19. BMJ, 2020, vol. 369: m1313. doi: 10.1136/bmj.m1313
9. Berthet J. Scientific work of Christian de Duve. Bull. Mem. Acad. R. Med. Belg., 2007, vol. 162, no. 10–12, pp. 499–504.
10. Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G., Ruan L., Song B., Cai Y., Wei M., Li X., Xia J., Chen N., Xiang J., Yu T., Bai T., Xie X., Zhang L., Li C., Yuan Y., Chen H., Li H., Huang H., Tu S., Gong F., Liu Y., Wei Y., Dong C., Zhou F., Gu X., Xu J., Liu Z., Zhang Y., Li H., Shang L., Wang K., Li K., Zhou X., Dong X., Qu Z., Lu S., Hu X., Ruan S., Luo S., Wu J., Peng L., Cheng F., Pan L., Zou J., Jia C., Wang J., Liu X., Wang S., Wu X., Ge Q., He J., Zhan H., Qiu F., Guo L., Huang C., Jaki T., Hayden F.G., Horby P.W., Zhang D., Wang C. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N. Engl. J. Med., 2020. doi: 10.1056/NEJMoa2001282
11. CDC. Coronavirus (COVID-19). URL: https://www.cdc.gov/coronavirus/2019-nCoV/index.html
12. CDC. Severe Acute Respiratory Syndrome (SARS). URL: https://www.cdc.gov/sars
13. Chan J.F., Yao Y., Yeung M.L., Deng W., Bao L., Jia L., Li F., Xiao C., Gao H., Yu P., Cai J.P., Chu H., Zhou J., Chen H., Qin C., Yuen K.Y. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J. Infect. Dis., 2015, vol. 212, pp. 1904–1913. doi: 10.1093/infdis/jiv392
14. Cochrane Library. Coronavirus (COVID-19). URL: https://www.cochranelibrary.com/covid-19
15. Coronavirus disease 2019 (COVID-19): a guide for U.K. GPs. BMJ, 2020, vol. 368: m800. doi: 10.1136/bmj.m800
16. De Wilde A.H., Jochmans D., Posthuma C.C., Zevenhoven-Dobbe J.C., van Nieuwkoop S., Bestebroer T.M., van den Hoogen B.G., Neyts J., Snijder E.J. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother., 2014, vol. 58, pp. 4875–4884.
17. Delang L., Abdelnabi R., Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res., 2018, vol. 153, pp. 85–94. doi: 10.1016/j.antiviral.2018.03.003
18. European Medicines Agency. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes. URL: https://www.ema.europa.eu/en/news/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trialsemergency-use-programmes
19. Falzarano D., de Wit E., Rasmussen A.L., Feldmann F., Okumura A., Scott D.P., Brining D., Bushmaker T., Martellaro C., Baseler L., Benecke A.G., Katze M.G., Munster V.J., Feldmann H. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med., 2013, vol. 19, pp. 1313–1317. doi: 10.1038/nm.3362
20. Fludase — Experimental Antiviral Drug for Influenza. URL: https://www.clinicaltrialsarena.com/projects/fludase
21. Garcia Borrega J., G ö del P., R ü ger M.A., Onur Ö .A., Shimabukuro-Vornhagen A., Kochanek M., B ö ll B. In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy. HemaSphere, 2019, vol. 3, no. 2: e191. doi: 10.1097/HS9.0000000000000191
22. Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H., Spitters C., Ericson K., Wilkerson S., Tural A., Diaz G., Cohn A., Fox L., Patel A., Gerber S.I., Kim L., Tong S., Lu X., Lindstrom S., Pallansch M.A., Weldon W.C., Biggs H.M., Uyeki T.M., Pillai S.K.; Washington State-nCoV Case Investigation Team. First case of 2019 novel Coronavirus in the United States. N. Engl. J. Med., 2020, vol. 382, pp. 929–936. doi: 10.1056/NEJMoa2001191
23. Keyaerts E., Vijgen L., Maes P., Neyts J., Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Commun., 2004, vol. 323, pp. 264–268. doi: 10.1016/j.bbrc.2004.08.085
24. Marjuki H., Mishin V.P., Chesnokov A.P., De La Cruz J.A., Fry A.M., Villanueva J., Gubareva L.V. An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality. J. Infect. Dis., 2014, vol. 210, no. 3, pp. 435-440. doi: 10.1093/infdis/jiu105
25. Markham A., Keam S.J. Danoprevir: first global approval. Drugs, 2018, vol. 78, no. 12, pp. 1271–1276. doi: 10.1007/s40265-018-0960-0
26. McChesney E.W. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am. J. Med., 1983, vol. 75, pp. 11–18. DOI: 10.1016/0002-9343(83)91265-2
27. Mingo R.M., Simmons J.A., Shoemaker C.J., Nelson E.A., Schornberg K.L., D’Souza R.S., Casanova J.E., White J.M. Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step. J. Virol., 2015, vol. 89, pp. 2931–2943. doi: 10.1128/JVI.03398-14
28. Mulangu S., Dodd L.E., Davey R.T. Jr, Tshiani Mbaya O., Proschan M., Mukadi D., Lusakibanza Manzo M., Nzolo D., Tshomba Oloma A., Ibanda A., Ali R., Coulibaly S., Levine A.C., Grais R., Diaz J., Lane H.C., Muyembe-Tamfum J.J.; PALM Writing Group, Sivahera B., Camara M., Kojan R., Walker R., Dighero-Kemp B., Cao H., Mukumbayi P., Mbala-Kingebeni P., Ahuka S., Albert S., Bonnett T., Crozier I., Duvenhage M., Proffitt C., Teitelbaum M., Moench T., Aboulhab J., Barrett K., Cahill K., Cone K., Eckes R., Hensley L., Herpin B., Higgs E., Ledgerwood J., Pierson J., Smolskis M., Sow Y., Tierney J., Sivapalasingam S., Holman W., Gettinger N., Vallée D., Nordwall J; PALM Consortium Study Team. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med., 2019, vol. 381, pp. 2293–2303. doi: 10.1056/NEJMoa1910993
29. Patel A.B, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. What is the evidence? JAMA, 2020. doi:10.1001/jama.2020.4812
30. Savarino А., Trani D., Donatelli I., Cauda R., Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect. Dis., 2006, vol. 6, pp. 67–69. doi: 10.1016/S1473-3099(06)70361-9
31. Schrezenmeier E., Dorner Е. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol., 2020, vol. 16, pp. 155–166. doi: 10.1038/s41584-020-0372-x
32. Sheahan T.P., Sims A.C., Leist S.R., Schä fer A., Won J., Brown A.J., Montgomery S.A., Hogg A., Babusis D., Clarke M.O., Spahn J.E., Bauer L., Sellers S., Porter D., Feng J.Y., Cihlar T., Jordan R., Denison M.R., Baric R.S. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun., 2020, vol. 11, no. 1: 222. doi: 10.1038/s41467-019-13940-6
33. Tchesnokov E., Feng Y., Porter D., Gö tte M. Mechanism of inhibition of Ebola virus RNA-dependent RNA Polymerase by remdesivir. Viruses, 2019, vol. 11, no. 4: E326. doi: 10.3390/v11040326
34. Vincent M.J., Bergeron E., Benjannet S., Erickson B.R., Rollin P.E., Ksiazek T.G., Seidah N.G., Nichol S.T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J., 2005, vol. 2: 69. doi: 10.1186/1743-422X-2-69
35. WHO. Coronavirus disease (COVID-19) Pandemic. URL: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
36. Yao T.T., Qian J.D., Zhu W.Y., Wang Y., Wang G.Q. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus — a possible reference for coronavirus disease-19 treatment option. J. Med. Virol., 2020. doi: 10.1002/jmv.25729
37. Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P., Liu X., Zhao L., Dong E., Song C., Zhan S., Lu R., Li H., Tan W., Liu D. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis., 2020: ciaa237. doi: 10.1093/cid/ciaa237
38. Yazdany J., Kim A.H.J. Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann. Intern. Med., 2020. doi: 10.7326/M20-1334
39. Zhai P., Ding Y., Wu X., Long J., Zhong Y., Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int. J. Antimicrob. Agents, 2020: 105955. doi: 10.1016/j.ijantimicag.2020.105955
40. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Chen H.D., Chen J., Luo Y., Guo H., Jiang R.D., Liu M.Q., Chen Y., Shen X.R., Wang X., Zheng X.S., Zhao K., Chen Q.J., Deng F., Liu L.L., Yan B., Zhan F.X., Wang Y.Y., Xiao G.F., Shi Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, vol. 579, no. 7798, pp. 270–273. doi: 10.1038/s41586-020-2012-7
